Sage Therapeutics and Biogen Announce Plans to Submit a New Drug Application (NDA) for Zuranolone to the U.S. Food & Drug Administration in the Second Half of 2022 with Rolling Submission Expected
Go back to Sage Therapeutics and Biogen Announce Plans to Submit a New Drug Application (NDA) for Zuranolone to the U.S. Food & Drug Administration in the Second Half of 2022 with Rolling Submission Expected| BIOGEN IDEC Inc. (NASDAQ: BIIB) | Delayed: 215.50 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $215.50 | 52 Week High | $333.65 | |||
| Open | $215.50 | 52 Week Low | $223.02 | |||
| Day High | $215.50 | P/E | 27.59 | |||
| Day Low | $215.50 | EPS | $7.81 | |||
| Volume | 328 | |||||
| Sagebrush Gold Ltd. (NASDAQ: SAGE) | Delayed: 8.68 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $8.68 | 52 Week High | $62.64 | |||
| Open | $8.68 | 52 Week Low | $26.28 | |||
| Day High | $8.68 | P/E | N/A | |||
| Day Low | $8.68 | EPS | $-0.94 | |||
| Volume | 100 | |||||
